Oral histoplasmosis: An unusual presentation

Head and Neck

Volumn 31, Issue 2, 2009, Pages 274-277

  Narayana, Nagamani ^a   Gifford, Ryan ^b   Giannini, Peter ^a   Casey, John ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b Private Practice   (United States)

Author keywords

Atypical lymphocytic proliferation; Immunosuppressive medications; Infliximab; Oral histoplasmosis; TNF alpha antagonists

Indexed keywords

AMOXICILLIN; CEFALEXIN; CLINDAMYCIN; INFLIXIMAB; ITRACONAZOLE; METHENAMINE; TUMOR NECROSIS FACTOR ALPHA;

AGED; ANAMNESIS; ARTICLE; BRONCHITIS; CASE REPORT; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; FEMALE; FOLLOW UP; GINGIVA ULCER; HISTOPATHOLOGY; HISTOPLASMA CAPSULATUM; HISTOPLASMOSIS; HUMAN; HUMAN TISSUE; LABORATORY TEST; LYMPHOMA; MICROSCOPY; MOUTH EXAMINATION; PERIODONTITIS; PRESCRIPTION; PRIORITY JOURNAL; RARE DISEASE; SILVER STAINING; SWELLING; TISSUE GRAFT; TOOTH PROSTHESIS; TREATMENT OUTCOME;

AGED; ANTIFUNGAL AGENTS; FEMALE; HISTOPLASMOSIS; HUMANS; ITRACONAZOLE; MOUTH DISEASES;

EID: 59449109435     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.20882     Document Type: Article

References (8)

1. Kurowski R, Ostapchuk M. Overview of histoplasmosis. Am Fam Physician 2002;66:2247-2252.
2. Valle ACF, Moreira LC, Almedida-Paes R, et al. Chronic disseminated histoplasmosis with lesions restricted to the mouth: case report. Rev Inst Med Trop S Paulo 2006;48:113-116.
3. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004;38:1261-1265.
4. Wallis RS, Ehlers S. Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab. Semin Arthritis Rheum 2005;34(Suppl 1):34-38.
5. Bakleh M, Tleyjeh I, Matteson EL, Osmon DR, Berbari EF. Infectious complications of tumor necrosis factor-alpha antagonists. Int J Dermatol 2005;44:443-448.
6. Ehlers S. Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept. Clin Infect Dis 2005;41(Suppl 3):S199-S203.
7. Furst DE, Wallis R, Broder M, Beenhouwer DO. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum 2006;36:159-167.
8. Setoguchi S, Solomon DH, Weinblatt ME, et al. Arthritis Rheuma 2006;54:2757-2764.